[go: up one dir, main page]

AR032261A1 - Metodo para obtener (3-cian-1h-indol-7-il)-[4-(4-fluorfenetil)-piperazin-1-il]-metanona y sus sales - Google Patents

Metodo para obtener (3-cian-1h-indol-7-il)-[4-(4-fluorfenetil)-piperazin-1-il]-metanona y sus sales

Info

Publication number
AR032261A1
AR032261A1 ARP020100222A ARP020100222A AR032261A1 AR 032261 A1 AR032261 A1 AR 032261A1 AR P020100222 A ARP020100222 A AR P020100222A AR P020100222 A ARP020100222 A AR P020100222A AR 032261 A1 AR032261 A1 AR 032261A1
Authority
AR
Argentina
Prior art keywords
salts
piperazin
fluorfenetil
metanone
cian
Prior art date
Application number
ARP020100222A
Other languages
English (en)
Inventor
Helene Crassier
Henning Boettcher
Bathe Andreas Dr
Steffen Schneider
Uwe Eckert
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR032261A1 publication Critical patent/AR032261A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/04—Preparation of lactams from or via oximes by Beckmann rearrangement
    • C07D201/06—Preparation of lactams from or via oximes by Beckmann rearrangement from ketones by simultaneous oxime formation and rearrangement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método para obtener (3-ciano-1H-indol-7-il)-[4-(4-fluorfenetil)-piperazin-1-il]-metanona y sus sales, caracterizado porque se convierte un indoléster de la formula (1) donde R tiene el significado mencionado en la reivindicacion 1, en los pasos (1) a (4) de acuerdo con la reivindicacion 1, en ácido 3-ciano-1H-indol-7-carboxílico y se convierte este con 1-[2-(4-fluor-fenil)-etil]-piperazina o sus sales en el producto.
ARP020100222A 2001-01-23 2002-01-23 Metodo para obtener (3-cian-1h-indol-7-il)-[4-(4-fluorfenetil)-piperazin-1-il]-metanona y sus sales AR032261A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10102944A DE10102944A1 (de) 2001-01-23 2001-01-23 Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen

Publications (1)

Publication Number Publication Date
AR032261A1 true AR032261A1 (es) 2003-10-29

Family

ID=7671481

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100222A AR032261A1 (es) 2001-01-23 2002-01-23 Metodo para obtener (3-cian-1h-indol-7-il)-[4-(4-fluorfenetil)-piperazin-1-il]-metanona y sus sales

Country Status (29)

Country Link
US (1) US7312342B2 (es)
EP (1) EP1353906B1 (es)
JP (1) JP4215195B2 (es)
KR (1) KR100820763B1 (es)
CN (1) CN1213029C (es)
AR (1) AR032261A1 (es)
AT (1) ATE269849T1 (es)
AU (1) AU2002219220B2 (es)
BR (1) BR0116816A (es)
CA (1) CA2435426C (es)
CZ (1) CZ20032202A3 (es)
DE (2) DE10102944A1 (es)
DK (1) DK1353906T3 (es)
EC (1) ECSP034737A (es)
ES (1) ES2223738T3 (es)
HU (1) HUP0401039A3 (es)
IL (2) IL157061A0 (es)
MX (1) MXPA03006534A (es)
MY (1) MY126252A (es)
NZ (1) NZ527779A (es)
PL (1) PL209416B1 (es)
PT (1) PT1353906E (es)
RU (1) RU2295519C2 (es)
SK (1) SK286565B6 (es)
TR (1) TR200402142T4 (es)
TW (1) TW588044B (es)
UA (1) UA74039C2 (es)
WO (1) WO2002059092A1 (es)
ZA (1) ZA200306540B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10246357A1 (de) * 2002-10-04 2004-04-15 Merck Patent Gmbh Verwendung von 5-HT2Rezeptorantagonisten
DE102004047517A1 (de) * 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
CN101437793B (zh) * 2006-05-05 2012-08-22 默克专利股份有限公司 结晶的（3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）哌嗪-1-基]甲酮磷酸盐
CA2652215A1 (en) * 2006-05-05 2007-11-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
CN102816104B (zh) * 2012-08-30 2014-05-21 浙江大学 一种3-氰基吲哚类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH421107A (de) * 1963-06-04 1966-09-30 Sandoz Ag Verfahren zur Herstellung neuer heterocyclischer Verbindungen
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines

Also Published As

Publication number Publication date
DE60104024T2 (de) 2005-07-07
ZA200306540B (en) 2004-09-02
JP2004519466A (ja) 2004-07-02
CN1487923A (zh) 2004-04-07
PL209416B1 (pl) 2011-08-31
DK1353906T3 (da) 2004-10-11
UA74039C2 (en) 2005-10-17
HUP0401039A2 (hu) 2004-08-30
DE10102944A1 (de) 2002-07-25
RU2295519C2 (ru) 2007-03-20
ECSP034737A (es) 2003-09-24
HUP0401039A3 (en) 2008-05-28
EP1353906B1 (en) 2004-06-23
CA2435426A1 (en) 2002-08-01
ATE269849T1 (de) 2004-07-15
EP1353906A1 (en) 2003-10-22
DE60104024D1 (de) 2004-07-29
KR20030068590A (ko) 2003-08-21
PT1353906E (pt) 2004-11-30
TW588044B (en) 2004-05-21
MXPA03006534A (es) 2003-09-22
MY126252A (en) 2006-09-29
CZ20032202A3 (cs) 2004-01-14
IL157061A0 (en) 2004-02-08
US7312342B2 (en) 2007-12-25
ES2223738T3 (es) 2005-03-01
IL157061A (en) 2009-09-01
CN1213029C (zh) 2005-08-03
KR100820763B1 (ko) 2008-04-10
US20040063723A1 (en) 2004-04-01
CA2435426C (en) 2009-10-27
BR0116816A (pt) 2004-01-27
SK10462003A3 (sk) 2003-12-02
JP4215195B2 (ja) 2009-01-28
RU2003124068A (ru) 2005-01-10
SK286565B6 (sk) 2009-01-07
WO2002059092A1 (en) 2002-08-01
HK1063182A1 (en) 2004-12-17
TR200402142T4 (tr) 2004-10-21
NZ527779A (en) 2004-12-24
AU2002219220B2 (en) 2007-01-11
PL364392A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
PL338129A1 (en) Crystalline form of a derivative of n-phenyl-2-dipyrimidin amine, methods of obtaining same and apllication thereof
EA200100826A1 (ru) 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
AR082864A2 (es) Preparacion de compuestos de aminopirimidina
BR0214805A (pt) Lama viscosa de alta perda de fluido solúvel em ácido para circulação perdida
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
SE8207425D0 (sv) 2-(4-((4,4-dialkyl-2,6-piperidindion-1-yl)butyl)-1-piperazinyl)pyrimidiner
EP1386912A4 (en) CYCLIC AMIDINE DERIVATIVES
DE69809187D1 (de) Metalloproteinase-Inhibitoren
EA200300337A1 (ru) Полиарилкарбоксамиды, применимые в качестве агентов, снижающих содержание липидов
EA200971046A1 (ru) Новые соли пиперазина в качестве d/d-антагонистов
DE602004022352D1 (de) Verwendung von 1-(2-Ethylhexyl)-Glycerin für die Desinfektion von Oberflächen oberhalb Raumtemperatur
AR012102A1 (es) Derivados de 2-(iminometil)amino-fenilo, su preparacion, uso de los mismos para la fabricacion de medicamentos y composiciones farmaceuticas que los contienen.
CO5601045A2 (es) Procedimiento para la fabricacion de compuestos organicos
AR032261A1 (es) Metodo para obtener (3-cian-1h-indol-7-il)-[4-(4-fluorfenetil)-piperazin-1-il]-metanona y sus sales
DE60308888D1 (de) Injizierbare 2,6-diisopropylphenol enthaltende anästhetische zusammensetzung und verfahren
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
ECSP045291A (es) Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas
HUP0102931A2 (hu) Új N-(triazolil-metil)-piperazin-származékok mint neurokininreceptor-antagonisták
MX2020012108A (es) Un proceso para la preparacion estereoselectiva de quiral 2-[(hetero)arilalquilsulfanil]pirimidinas y productos que se obtienen de esta.
AR026677A1 (es) Metodo para obtener 5-(1-piperazinil)-benzofuran-2-carboxamida por aminacion catalizada por un metal de transicion.
HRP20020470B1 (hr) POSTUPAK PRIREĐIVANJA {2-[4-(α-FENIL-p-KLORBENZIL)-PIPERAZIN-1-IL]ETOKSI} OCTENE KISELINE I NOVIH INTERMEDIJERA
ATE482698T1 (de) Vermeidung von vorhofflimmern (af) mit der verwendung von statin
BG35747A3 (bg) Метод за получаване на 2- 4-(2- фуроил)-пиперазин- 1- ил- 4- амино- 6,7- диметоксихиназолин
DE50011502D1 (de) Verwendung von Emulgatoren in Bitumenemulsionen
KR920008020A (ko) 피레라진 유도체

Legal Events

Date Code Title Description
FB Suspension of granting procedure